are asymptomatic with respect to anginal symptoms, we wonder whether other symptoms such as hypotension, hypertension or cramps have occurred during blood sampling.
Reply Sir, We appreciate your inquiries regarding our study [1] . The primary purpose of our study was to measure the incidence of troponin I (TnI) elevation in end-stage renal failure using a sensitive assay and assess the variability of TnI over time.
We did not find that serum albumin and hemoglobin, which are inversely correlated with inflammation in end-stage renal failure [2, 3] , had any association with TnI. We did not measure c-reactive protein levels or other inflammatory markers nor did we assess intradialytic blood pressure fluctuations or cramping symptoms for our study. No angiography was performed in response to an elevated TnI, even in the AMI range, as patients remained asymptomatic. We are in the process of gathering follow-up data regarding our patients to determine if there was an association of positive TnI with cardiovascular outcomes over a 1-year period. , an alternative approach would be to identify those individuals with changing cTnI concentrations. In those with symptoms suggestive of acute coronary syndrome in the emergency setting, a 30% change in concentration using the same cTnI assay (VITROS Troponin I ES) improved both the specificity for AMI detection and risk stratification [4] . Thus, it would be of interest to evaluate if employing this percent change criteria by itself or in conjugation with the 99th percentile to this population identified more individuals with change as opposed to just using the predefined ranges.
Another point of clarification is that the cTnI assay used by Kumar et al. was not a high-sensitivity assay. Highsensitivity assays are different from current in-use assays in two fundamental ways: (i) the majority of healthy individuals will have measurable concentrations of cardiac troponin using these assays and (ii) the units are different, with concentrations reported in nanogram per liter or picogram per milliliter (pg/mL) as opposed to nanogram per milliliter (ng/mL) for current assays [5] . To date, only one highsensitivity assay (hs-cTnT) has been measured in ESRD patients, with 100% of patients (n = 32) having at least one elevation above the 99th percentile cutoff over a 6-month period [2] . Thus, interpretation may prove to be even more challenging when using highsensitivity assays in those with ESRD. Future studies measuring high-sensitivity cardiac troponin assays in this population will need to consider what constitutes a significant change in concentration or possibly alternative cutoffs based on adverse outcomes [5] .
